AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23561959 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure (Control)
Number of subjects: 21
Study 23561959 — intervention group
Group type: EXPERIMENTAL
Intervention: ABMSCT
Number of subjects: 21
Study 22341794 — intervention group
Group type: EXPERIMENTAL
Intervention: EBRT+HDR-BTb
Number of subjects: 218
Study 22341794 — intervention group
Group type: COMPARATOR
Intervention: EBRT alone
Number of subjects: 218
Study 21216832 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocardial LV pacing from the best endocardial site
Number of subjects: 15
Study 21216832 — intervention group
Group type: COMPARATOR
Intervention: Conventional CRT
Number of subjects: 15
Study 21216832 — intervention group
Group type: EXPERIMENTAL
Intervention: All LV pacing modes
Number of subjects: 15
Study 21216832 — intervention group
Group type: EXPERIMENTAL
Intervention: LV stimulation outside areas of slow conduction
Number of subjects: 15
Study 18647128 — intervention group
Group type: EXPERIMENTAL
Intervention: CBGT+EX (exercise-enhanced cognitive behavioural group therapy)
Number of subjects: 73
Study 18647128 — intervention group
Group type: COMPARATOR
Intervention: CBGT+ED (usual cognitive behavioural group therapy plus nutrition education)
Number of subjects: 73
Study 18647128 — intervention group
Group type: EXPERIMENTAL
Intervention: CBGT+EX
Number of subjects: 73
Study 16948354 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast, 5-mg tablets for 1 month
Number of subjects: 30
Study 16948354 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast, before treatment
Number of subjects: 30
Study 16948354 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 12974853 — intervention group
Group type: EXPERIMENTAL
Intervention: Cementation with 100 N seating force (Group 1)
Number of subjects: 30
Study 12974853 — intervention group
Group type: EXPERIMENTAL
Intervention: Cementation with 10 N force and dentine sealing (Group 2)
Number of subjects: 30
Study 12974853 — intervention group
Group type: EXPERIMENTAL
Intervention: Cementation with 10 N force, dentine sealing, and oscillating seating force (Group 3)
Number of subjects: 30
Study 10920334 — intervention group
Group type: EXPERIMENTAL
Intervention: Cord blood collection before placental delivery
Number of subjects: 40
Study 10920334 — intervention group
Group type: COMPARATOR
Intervention: Cord blood collection after placental delivery
Number of subjects: 40
Study 8824057 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (AMI), 5 mg/kg per day
Number of subjects: 31
Study 8824057 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 1411286 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemoccult‐II screening
Number of subjects: 61938
Study 6726307 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 51
Study 6726307 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive counseling
Number of subjects: 51
Study 6726307 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 51
Study 31092695 — intervention group
Group type: EXPERIMENTAL
Intervention: ACCi-1 (acetyl-CoA carboxylase inhibitor), dosed orally for 2 weeks
Number of subjects: 0
Study 31092695 — intervention group
Group type: EXPERIMENTAL
Intervention: ACCi-1 (acetyl-CoA carboxylase inhibitor)
Number of subjects: 0
Study 31092695 — intervention group
Group type: COMPARATOR
Intervention: Individuals with acne vulgaris
Number of subjects: 0
Study 29214348 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser-assisted hatching
Number of subjects: 308
Study 29214348 — intervention group
Group type: COMPARATOR
Intervention: No laser-assisted hatching
Number of subjects: 308
Study 26338465 — intervention group
Group type: EXPERIMENTAL
Intervention: CogniPlus program combined with balance training
Number of subjects: 80
Study 26338465 — intervention group
Group type: COMPARATOR
Intervention: Balance training alone
Number of subjects: 80
Study 25230962 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracameral dexamethasone (0.4 mg/0.1 ml)
Number of subjects: 60
Study 25230962 — intervention group
Group type: COMPARATOR
Intervention: Intracameral triamcinolone acetonide (2 mg/0.05 ml)
Number of subjects: 60
Study 22617588 — intervention group
Group type: EXPERIMENTAL
Intervention: Excessive early gestational weight gain
Number of subjects: 7985
Study 22617588 — intervention group
Group type: COMPARATOR
Intervention: Nonexcessive early gestational weight gain
Number of subjects: 7985
Study 20470679 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D computer model group (n = 50)
Number of subjects: 100
Study 20470679 — intervention group
Group type: COMPARATOR
Intervention: Standard written instruction group (SWI group) (n = 50)
Number of subjects: 100
Study 18006530 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil at target Ce of 4 ng ml(‐1)
Number of subjects: 128
Study 18006530 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil at target Ce of 6 ng ml(‐1)
Number of subjects: 128
Study 18006530 — intervention group
Group type: COMPARATOR
Intervention: Control (normal saline)
Number of subjects: 128
Study 18006530 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil at target Ce of 2 ng ml(‐1)
Number of subjects: 128
Study 16102942 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 0
Study 16102942 — intervention group
Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 0
Study 12230319 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone
Number of subjects: 0
Study 12230319 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine
Number of subjects: 0
Study 12230319 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-2
Number of subjects: 0
Study 12230319 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary management
Number of subjects: 0
Study 12230319 — intervention group
Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition
Number of subjects: 0
Study 12230319 — intervention group
Group type: EXPERIMENTAL
Intervention: Intestinal transplant
Number of subjects: 0
Study 10200006 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine (10 mg daily)
Number of subjects: 23
Study 10200006 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine (10 mg daily)
Number of subjects: 23
Study 10200006 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 7774173 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass ionomer cement (GIC) applied by dentist
Number of subjects: 1264
Study 7774173 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass ionomer cement (GIC) applied by trained teachers
Number of subjects: 1264
Study 7774173 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% HF solution applied three times
Number of subjects: 1264
Study 7774173 — intervention group
Group type: EXPERIMENTAL
Intervention: Delton resin-based sealant
Number of subjects: 1264
Study 7774173 — intervention group
Group type: EXPERIMENTAL
Intervention: GIC applied by dentist (12-13 yr-olds)
Number of subjects: 1264
Study 7774173 — intervention group
Group type: EXPERIMENTAL
Intervention: GIC applied by teachers (12-13 yr-olds)
Number of subjects: 1264
Study 7774173 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% HF solution (12-13 yr-olds)
Number of subjects: 1264
Study 7774173 — intervention group
Group type: COMPARATOR
Intervention: Control group (younger age group)
Number of subjects: 1264
Study 7774173 — intervention group
Group type: COMPARATOR
Intervention: Control group (12-13 yr-olds)
Number of subjects: 1264
Study 2182310 — intervention group
Group type: EXPERIMENTAL
Intervention: RU486 alone (600mg in a single oral dose)
Number of subjects: 316
Study 2182310 — intervention group
Group type: EXPERIMENTAL
Intervention: RU486 and PG (1 mg suppository)
Number of subjects: 316
Study 2182310 — intervention group
Group type: EXPERIMENTAL
Intervention: RU486 and PG
Number of subjects: 316
Study 2182310 — intervention group
Group type: COMPARATOR
Intervention: RU486 alone
Number of subjects: 316
Study 7356891 — intervention group
Group type: EXPERIMENTAL
Intervention: 160 mg propranolol
Number of subjects: 10
Study 7356891 — intervention group
Group type: EXPERIMENTAL
Intervention: 160 mg L.A. propranolol
Number of subjects: 10
Study 7356891 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 10
Study 7356891 — intervention group
Group type: EXPERIMENTAL
Intervention: L.A. propranolol
Number of subjects: 10
Study 30770892 — intervention group
Group type: EXPERIMENTAL
Intervention: Delta-9-tetrahydrocannabinol (Δ9-THC; 1.19 mg/2 ml)
Number of subjects: 16
Study 30770892 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 30770892 — intervention group
Group type: EXPERIMENTAL
Intervention: Delta-9-tetrahydrocannabinol (Δ9-THC)
Number of subjects: 16
Study 30739626 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg/d Mg as magnesium oxide (n=27)
Number of subjects: 54
Study 28936036 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular dentures with soft denture liner
Number of subjects: 28
Study 28936036 — intervention group
Group type: COMPARATOR
Intervention: Mandibular dentures without soft denture liner (control)
Number of subjects: 28
Study 25912390 — intervention group
Group type: EXPERIMENTAL
Intervention: Staged PCI
Number of subjects: 125
Study 23721562 — intervention group
Group type: EXPERIMENTAL
Intervention: Maudsley Model of Treatment for Adults with Anorexia Nervosa (MANTRA)
Number of subjects: 138
Study 23721562 — intervention group
Group type: COMPARATOR
Intervention: Specialist Supportive Clinical Management (SSCM)
Number of subjects: 138
Study 20336636 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-Solving Therapy (PST)
Number of subjects: 98
Study 19448203 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch (HES) 130/0.4
Number of subjects: 115
Study 19448203 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 115
Study 17106140 — intervention group
Group type: EXPERIMENTAL
Intervention: CR‐ISMN (40 mg once daily)
Number of subjects: 31
Study 17106140 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 12751378 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery (SR)
Number of subjects: 94
Study 12751378 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole brain irradiation (WBI)
Number of subjects: 94
Study 12751378 — intervention group
Group type: COMPARATOR
Intervention: High-dose interleukin-2 (IL-2) and interferon-alpha (IFN-alpha) therapy
Number of subjects: 94
Study 12751378 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 94
Study 10846781 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacterial vaginosis (36 patients, 32%)
Number of subjects: 112
Study 10846781 — intervention group
Group type: COMPARATOR
Intervention: Normal flora (76 patients, 68%)
Number of subjects: 112
Study 10846781 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical length < 25 mm
Number of subjects: 112
Study 10846781 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall preterm delivery rate
Number of subjects: 112
Study 10846781 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical length measured by transvaginal ultrasonography
Number of subjects: 112
Study 9322520 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg of lamivudine
Number of subjects: 51
Study 9322520 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of lamivudine
Number of subjects: 51
Study 9322520 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg of lamivudine
Number of subjects: 51
Study 9322520 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine (all doses)
Number of subjects: 51
Study 8436459 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 22
Study 8436459 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 22
Study 3087293 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoimmunotherapy with MMC, 5‐FU and OK‐432 (group B)
Number of subjects: 99
Study 3087293 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy with MMC and 5‐FU (group A)
Number of subjects: 99
Study 3087293 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone (group C)
Number of subjects: 99
Study 29022746 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Number of subjects: 2313
Study 29022746 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Number of subjects: 2313
Study 29022746 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2313
Study 27367724 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic supplementation (Lactobacillus reuteri with guar gum and inulin for three months)
Number of subjects: 50
Study 27367724 — intervention group
Group type: COMPARATOR
Intervention: Nutritional counseling alone
Number of subjects: 50
Study 24890738 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium Respimat® 5 μg
Number of subjects: 149
Study 24890738 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium Respimat® 2.5 μg
Number of subjects: 149
Study 24890738 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium Respimat® 1.25 μg
Number of subjects: 149
Study 24890738 — intervention group
Group type: COMPARATOR
Intervention: Placebo Respimat®
Number of subjects: 149
Study 23018285 — intervention group
Group type: EXPERIMENTAL
Intervention: Avagacestat 200 mg
Number of subjects: 34
Study 23018285 — intervention group
Group type: EXPERIMENTAL
Intervention: Avagacestat 400 mg
Number of subjects: 34
Study 23018285 — intervention group
Group type: EXPERIMENTAL
Intervention: Avagacestat 50 mg
Number of subjects: 34
Study 23018285 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 20732631 — intervention group
Group type: EXPERIMENTAL
Intervention: Teacher-delivered personality-targeted intervention
Number of subjects: 2506
Study 20732631 — intervention group
Group type: COMPARATOR
Intervention: Nontreatment condition
Number of subjects: 2506
Study 18183940 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 0
Study 15373868 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic scalpel
Number of subjects: 21
Study 15373868 — intervention group
Group type: COMPARATOR
Intervention: Bipolar diathermy
Number of subjects: 21
Study 11240120 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast sensitivity in deaf subjects
Number of subjects: 0
Study 11240120 — intervention group
Group type: COMPARATOR
Intervention: Contrast sensitivity in hearing subjects
Number of subjects: 0
Study 11240120 — intervention group
Group type: COMPARATOR
Intervention: Contrast sensitivity in hearing native signers
Number of subjects: 0
Study 9322631 — intervention group
Group type: COMPARATOR
Intervention: Prepidil (intracervical prostaglandin E2 gel)
Number of subjects: 73
Study 9322631 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervidil (controlled-release hydrogel pessary)
Number of subjects: 73
Study 8173721 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftizoxime (1 gram single dose)
Number of subjects: 461
Study 8173721 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitin (3 doses of 2 grams)
Number of subjects: 461
Study 8173721 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftizoxime
Number of subjects: 461
Study 8173721 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitin
Number of subjects: 461
Study 8173721 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftizoxime and Cefoxitin
Number of subjects: 461
Study 2895596 — intervention group
Group type: EXPERIMENTAL
Intervention: Single small oral dose of a beta-adrenergic blocking agent (labetalol, atenolol, or oxprenolol)
Number of subjects: 128
Study 2895596 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 128
Study 29068040 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 MAC desflurane
Number of subjects: 36
Study 29068040 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 36
Study 29068040 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 MAC desflurane
Number of subjects: 36
Study 29068040 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 MAC desflurane
Number of subjects: 36
Study 28969655 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational interventions including lecture and group discussion along with standard well baby care
Number of subjects: 104
Study 28969655 — intervention group
Group type: COMPARATOR
Intervention: Standard well baby care
Number of subjects: 104
Study 25644349 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 IU/d of vitamin D3 supplementation
Number of subjects: 51
Study 25644349 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 IU/d of vitamin D3 supplementation
Number of subjects: 51
Study 25644349 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified, but implied as no supplementation)
Number of subjects: 51
Study 22562960 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g testosterone gel daily for 6 months
Number of subjects: 209
Study 22562960 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 209
Study 19395280 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin pump infusion line not changed for up to 100 hours
Number of subjects: 20
Study 18307075 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 93
Study 18307075 — intervention group
Group type: COMPARATOR
Intervention: Ritodrine
Number of subjects: 93
Study 17140521 — intervention group
Group type: EXPERIMENTAL
Intervention: ART method
Number of subjects: 217
Study 17140521 — intervention group
Group type: EXPERIMENTAL
Intervention: Carisolv
Number of subjects: 217
Study 17140521 — intervention group
Group type: COMPARATOR
Intervention: Rotating instruments (Control)
Number of subjects: 217
Study 12768426 — intervention group
Group type: EXPERIMENTAL
Intervention: Shot put performance
Number of subjects: 13
Study 12768426 — intervention group
Group type: EXPERIMENTAL
Intervention: One-arm seated shot put
Number of subjects: 13
Study 12768426 — intervention group
Group type: EXPERIMENTAL
Intervention: Elbow extensors' isokinetic torque
Number of subjects: 13
Study 12768426 — intervention group
Group type: EXPERIMENTAL
Intervention: Bench-press tests
Number of subjects: 13
Study 12768426 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimated arm muscle cross-sectional area
Number of subjects: 13
Study 11099990 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiarrhythmic conversion strategy (n = 27)
Number of subjects: 50
Study 11099990 — intervention group
Group type: COMPARATOR
Intervention: Rate-control strategy (n = 23)
Number of subjects: 50
Study 11099990 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiarrhythmic strategy
Number of subjects: 50
Study 11099990 — intervention group
Group type: COMPARATOR
Intervention: Rate-control strategy
Number of subjects: 50
Study 11099990 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiarrhythmic arm
Number of subjects: 50
Study 11099990 — intervention group
Group type: COMPARATOR
Intervention: Rate-control arm
Number of subjects: 50
Study 8958014 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal endosonography
Number of subjects: 17
Study 8958014 — intervention group
Group type: COMPARATOR
Intervention: Proctography
Number of subjects: 17
Study 1396252 — intervention group
Group type: EXPERIMENTAL
Intervention: Surfactant-TA (100 mg/kg) administered within 30 min of birth (early group)
Number of subjects: 32
Study 1396252 — intervention group
Group type: COMPARATOR
Intervention: Surfactant-TA (100 mg/kg) administered at 6 h of age (late group)
Number of subjects: 32
Study 1396252 — intervention group
Group type: EXPERIMENTAL
Intervention: Surfactant-TA (100 mg/kg) administered early
Number of subjects: 32
Study 4039775 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (MCL, Paspertin, loading infusion 0.5 mg/kg body wt./h over 2 h, maintenance infusion 0.25 mg/kg/h over 24 h)
Number of subjects: 22
Study 4039775 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (HAL, Haldol, 1/10 of MCL dosage)
Number of subjects: 22
Study 4039775 — intervention group
Group type: COMPARATOR
Intervention: Triflupromazine (TFP, Psyquil, 1/2 of MCL dosage)
Number of subjects: 22
Study 4039775 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (MCL)
Number of subjects: 22
Study 4039775 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (HAL)
Number of subjects: 22
Study 4039775 — intervention group
Group type: COMPARATOR
Intervention: Triflupromazine (TFP)
Number of subjects: 22
Study 31557306 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 604
Study 31557306 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 604
Study 31557306 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil
Number of subjects: 604
Study 30422789 — intervention group
Group type: EXPERIMENTAL
Intervention: Pro-drinking user-generated comments (UGCs) with high user engagement
Number of subjects: 120
Study 30422789 — intervention group
Group type: COMPARATOR
Intervention: Anti-drinking user-generated comments (UGCs) with high user engagement
Number of subjects: 120
Study 27219465 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured exercise training programme (SETP)
Number of subjects: 150
Study 27219465 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptives (3 mg drospirenone plus 30 μg ethinyloestradiol)
Number of subjects: 150
Study 27219465 — intervention group
Group type: COMPARATOR
Intervention: Polyvitamin tablets
Number of subjects: 150
Study 22385102 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination peel with fractional prickle coral calcium (FCR™)
Number of subjects: 16
Study 22809091 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed combination brimonidine-timolol (FCBT)
Number of subjects: 105
Study 22809091 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine tartrate 0.2%
Number of subjects: 105
Study 22809091 — intervention group
Group type: COMPARATOR
Intervention: Control (artificial tear)
Number of subjects: 105
Study 20138102 — intervention group
Group type: COMPARATOR
Intervention: 5-HTP administration
Number of subjects: 12
Study 20138102 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 17885522 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 360
Study 17885522 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 360
Study 15628945 — intervention group
Group type: EXPERIMENTAL
Intervention: Gliclazide (interchange group)
Number of subjects: 116
Study 15628945 — intervention group
Group type: COMPARATOR
Intervention: Glibenclamide (reference group)
Number of subjects: 116